Article thumbnail

A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720

By James S. McCarthy, Joanne Marjason, Suzanne Elliott, Paul Fahey, Gilles Bang, Elissa Malkin, Eveline Tierney, Hayley Aked-Hurditch, Christopher Adda, Nadia Cross, Jack S. Richards, Freya J. I. Fowkes, Michelle J. Boyle, Carole Long, Pierre Druilhe, James G. Beeson and Robin F. Anders
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant.
  2. (2005). A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
  3. (2007). A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII.
  4. (2008). A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
  5. (2001). A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.
  6. (1997). A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria.
  7. (2002). A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.
  8. (2006). A set of glycosylphosphatidyl inositol-anchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion.
  9. (1979). A simple sequentially rejective multiple test procedure.
  10. (2001). A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies.
  11. (2008). Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum.
  12. (2010). Adjuvant Technology Transfer Hub.
  13. (2009). Adjuvants for malaria vaccines.
  14. (2010). Allelespecific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria.
  15. (1988). An epitope recognised by inhibitory monoclonal antibodies that react with a 51 kilodalton merozoite surface antigen in Plasmodium falciparum.
  16. (2009). Artemisinin resistance in Plasmodium falciparum malaria.
  17. (1995). Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria.
  18. (2002). Association of the IgG response to Plasmodium falciparum merozoite protein (C-terminal 19 kD) with clinical immunity to malaria in the Brazilian Amazon region.
  19. (1990). Characterisation of an inhibitory monoclonal antibody-defined epitope on a malaria vaccine candidate antigen.
  20. (2004). Double staining of Plasmodium falciparum nucleic acids with hydroethidine and thiazole orange for cell cycle stage analysis by flow cytometry.
  21. (2000). Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers.
  22. (2005). Epitopespecific regulation of immunoglobulin class switching in mice immunized with malarial merozoite surface proteins.
  23. (2009). Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
  24. (2000). Functional analysis of proteins involved in Plasmodium falciparum merozoite invasion of red blood cells.
  25. (2007). Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
  26. (2006). High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
  27. (1995). Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass.
  28. (1999). Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant.
  29. (2006). Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum.
  30. (1988). Identification of two integral membrane proteins of Plasmodium falciparum.
  31. (1998). IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria.
  32. (2008). Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients.
  33. (2009). Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
  34. (2007). Longterm clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. PLoS
  35. (2005). Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.
  36. (2009). MVI-IDRI Collaboration Aims to ‘‘Boost’’ Malaria Vaccine Development.
  37. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
  38. (2010). Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults.
  39. (2005). Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.
  40. (2008). Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.
  41. (1999). Plasmodium falciparum isolates from infected pregnant women and children are associated with distinct adhesive and antigenic properties.
  42. (2009). Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils.
  43. (2011). Plasmodium falciparum msp1, msp2 and glurp allele frequency and diversity in sub-Saharan Africa.
  44. (2010). Recombinant protein vaccines against the asexual blood stages of Plasmodium falciparum.
  45. (1994). Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea.
  46. (2005). Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
  47. (2008). Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
  48. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS
  49. (2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.
  50. (2000). Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea.
  51. (2005). Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine,
  52. (1995). Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
  53. (1997). Selection of an adjuvant for vaccination with the malaria antigen, MSA-2.
  54. (2003). Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria.
  55. (1996). Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum.
  56. (1991). Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum.
  57. (1991). Structural diversity in the Plasmodium falciparum merozoite surface antigen 2.
  58. (2007). The importance of human FcgammaRI in mediating protection to malaria.
  59. (2006). The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody.
  60. (2009). The quantity and quality of African children’s IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.
  61. (2010). The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS medicine 7:
  62. (2008). Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies.
  63. (2009). World Malaria Report.